Typhoid
Conditions
Keywords
Typhoid conjugate vaccine, Vi-DT, Safety, Immunogenicity
Brief summary
This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose. The study objectives are: I. Demonstrate non-inferiority of Vi-DT compared to Typbar TCV® as measured by seroconversion rates of anti-Vi IgG ELISA antibody titers, 4 weeks after single dose (pooled immunogenicity of three lots of Vi-DT) II. Demonstrate the equivalence of immunogenicity as measured by anti-Vi IgG GMT of three lots of Vi-DT vaccine 4 weeks after single dose.
Detailed description
Subjects will be stratified according to age. The study procedure is as follows: Visit 1 (day-1 to -7): Screen participants by medical/medications history, physical examination, Vital signs, Urine pregnancy test (UPT) Visit 2 (day 0): Enroll, randomize and administer vaccine to eligible participants and assess participant safety by physical examination and Vital signs, Collect blood for immunogenicity assessments. Visit 3 (day 7): Check solicited adverse reaction 7 days post vaccination and Assess participant safety by physical examination and Vital signs Visit 4 (day 28): Assess participant safety by physical examination and Vital signs, Collect blood for immunogenicity assessments Visit 5 (day 84): Assess participant safety by physical examination and Vital signs Visit 6 (day 168): Assess participant safety by physical examination and Vital signs, Collect blood for immunogenicity assessments, and fill in study completion form in the absence of any safety concern. This study is observer-blind: vaccine administrator and vaccine safety evaluator will be two distinct persons to avoid bias of safety assessment. Trial staff other than the vaccine administrator. For retention: After vaccination, field health worker/designee will contact participant every day till Day 7 by physical visit or by phone call. Follow-up reminder calls will be done very frequently as per discretion of study staff until 24 weeks for all participant to assess participant safety.
Interventions
BIOLOGICALTest Vaccine Vi-DT Typhoid conjugate
* Manufacturer: SK Bioscience Co., Ltd. * Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid * Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial
BIOLOGICALControl Vaccine Typbar TCV®
* Manufacturer: Bharat Biotech * Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein * Dose: 0.5 ml
Sponsors
SK Bioscience Co., Ltd.
International Vaccine Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
This study is observer blind: 1. Vaccine administrator and vaccine safety evaluator at site will be two distinct persons. 2. Laboratory personnel who analyzes immunogenicity at sponsor is also blinded.
Intervention model description
Participants age 6 months to 45 years
Eligibility
Sex/Gender
ALL
Age
6 Months to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy participants 6 months to 45 years of age at enrollment 2. Participants/Parents/LAR who have voluntarily given informed consent/assent 3. Participants/Parents/LAR willing to follow the study procedures of the study and available for the entire duration of the study
Exclusion criteria
1. Child with a congenital abnormality 2. Subject concomitantly enrolled or scheduled to be enrolled in another trial 3. Known history of immune function disorders including immunodeficiency diseases (Known HIV infection or other immune function disorders) 4. Chronic use of systemic steroids (\>2 mg/kg/day or \>20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs 5. Receipt of blood or blood-derived products in the past 3 months 6. Subject with a previously ascertained or suspected disease caused by S. Typhi 7. Subject who have had household contact with/and or intimate exposure to an individual with laboratory-confirmed S. Typhi 8. Individual who has previously received a typhoid vaccine 9. Subject who has received or is expected to receive other vaccines from 1 month prior to IP vaccination to Visit 4 (approx.1 month post IP) except PVC booster as per EPI schedule 10. Known history or allergy to vaccines or other medications 11. History of uncontrolled coagulopathy or blood disorders 12. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the subject and interfere with the assessment of the study objectives 13. Any female participant who is lactating, pregnant\* or planning for pregnancy during the course of study period 14. Participants/Parents/LAR planning to move from the study area before the end of study period 15. As per Investigator's medical judgement individuals could be excluded from the study inspite of meeting all inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Seroconversion rate1 | 4 weeks (28 days) after vaccination of Vi-DT(pooled)/ Typbar TCV® compared to baseline (D0) | Defined as a 4-fold increase of serum anti-Vi IgG antibody titer |
| Geometric Mean Titers (GMT)1 | 4 weeks after vaccination of Vi-DT | Measurement of the Geometric Mean Titers (GMT) following 4 weeks after vaccination of three lots of Vi-DT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Seroconversion rate 3 | 4 weeks (28 days) after vaccination of Vi-DT(pooled) | Definded as a Seroconversion rates of anti-Vi IgG ELISA antibody titers after vaccination of three lots of Vi-DT. |
| Seroconversion rate 4 | 4 weeks (28 days) after vaccination of Vi-DT(pooled) | Definded as a Seroconversion rates of anti-Vi IgG ELISA antibody titers at 4 weeks (28 days) after vaccination of three lots of Vi-DT in each age strata |
| Geometric Mean Titers (GMT) 2 | 4 weeks and 24 weeks after vaccination of Vi-DT(pooled)/ Typbar TCV® | Measurement of the Geometric Mean Titers (GMT) following 4 weeks (28 days) and 24 weeks(168 days) after vaccination of Vi-DT (pooled)/ Typbar TCV® |
| Safety endpoints for solicited adverse events (reactogenicity) | 7days after vaccination of Vi-DT(pooled)/ Typbar TCV® | Proportion of participants with local and systemic solicited adverse events |
| Seroconversion rate 5 | 4 weeks (28 days) after vaccination of MR compared to baseline (D0) | Definded as IgG ELISA antibody titers for Measles (M), and Rubella (R) following single dose of MR a vaccine at baseline D0 and 4 weeks |
| Seroconversion rate 2 | 24 weeks (168 days) after vaccination of Vi-DT(pooled)/ Typbar TCV® compared to baseline (D0). | Defined as a 4-fold increase of serum anti-Vi IgG antibody titer |
Countries
Nepal
Outcome results
None listed